Litcius/Paper detail

Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects

Ming Guo, Daiying Zuo, Tianming Zhao, Xiangyü Li, Jianshuang Cao, Yuxuan Qiu, Shangfei Wei, Xin Zhai

2021European Journal of Medicinal Chemistry11 citationsDOIOpen Access PDF

Topics & Concepts

CeritinibChemistryROS1StereochemistryMutantFuranIC50PharmacophoreMutationCytotoxicityMolecular biologyCombinatorial chemistryBiochemistryAnaplastic lymphoma kinaseIn vitroGeneCancerGeneticsLung cancerBiologyAdenocarcinomaInternal medicineMedicineMalignant pleural effusionOrganic chemistryLung Cancer Treatments and MutationsCancer therapeutics and mechanismsLung Cancer Research Studies
Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects | Litcius